In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News' INVEST Digital Health conference in Dallas, healthcare leaders shared their insight on how startups can best serve their provider partners during these pilots.
Join over 3,200 global biopharma leaders, including 1,200+ investors and 350+ biotech innovators unveiling their latest breakthroughs at Biotech Showcase™, Jan 13–15, 2025.
During a panel at the MedCity News INVEST Digital Health conference, three healthcare execs shared advice to startups on how to pitch to employers. They need to know their worth, understand the problem they're solving, and think about issues globally.
By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024.
While fibrates are proven to lower triglyceride levels, which can serve as a biomarker for cardiovascular disease risk, several major clinical studies from the past 20 years have failed to show a benefit of fenofibrates over and above statins in further reducing heart-related events.
The current model of siloed, proprietary development is failing us. It's slow, expensive, and often results in technologies that never see the light of day. What if, instead, we embraced an open-source approach to medical device innovation?
In this episode, we address a judge's ruling against FTC's ban on non-compete clauses in employment contracts and its implications for healthcare workers. Also, Pfizer's launch of a digital platform providing easy access to providers and medications for migraine patients and vaccine seekers. Finally, Johnson & Johnson's attempt to modify its 340B drug discount program, which offers reduced prices on outpatient medications to hospitals serving uninsured patients.
No comments